SK4862000A3 - The use of 5-ht3 receptor antagonists - Google Patents

The use of 5-ht3 receptor antagonists Download PDF

Info

Publication number
SK4862000A3
SK4862000A3 SK486-2000A SK4862000A SK4862000A3 SK 4862000 A3 SK4862000 A3 SK 4862000A3 SK 4862000 A SK4862000 A SK 4862000A SK 4862000 A3 SK4862000 A3 SK 4862000A3
Authority
SK
Slovakia
Prior art keywords
alosetron
patients
ibs
pharmaceutically acceptable
women
Prior art date
Application number
SK486-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Allen Wayne Mangel
Allison Ruth Northcutt
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10820099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK4862000(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SK4862000A3 publication Critical patent/SK4862000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SK486-2000A 1997-10-07 1998-10-05 The use of 5-ht3 receptor antagonists SK4862000A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9721139.5A GB9721139D0 (en) 1997-10-07 1997-10-07 Medicaments
PCT/EP1998/006278 WO1999017755A2 (en) 1997-10-07 1998-10-05 Medicaments

Publications (1)

Publication Number Publication Date
SK4862000A3 true SK4862000A3 (en) 2001-01-18

Family

ID=10820099

Family Applications (1)

Application Number Title Priority Date Filing Date
SK486-2000A SK4862000A3 (en) 1997-10-07 1998-10-05 The use of 5-ht3 receptor antagonists

Country Status (36)

Country Link
US (3) US6284770B1 (et)
EP (1) EP1021174A2 (et)
JP (1) JP2001518495A (et)
KR (1) KR20010015707A (et)
CN (1) CN1281357A (et)
AP (1) AP2000001785A0 (et)
AR (1) AR017296A1 (et)
AU (1) AU750818B2 (et)
BR (1) BR9812886A (et)
CA (1) CA2305751A1 (et)
CO (1) CO5011096A1 (et)
DZ (1) DZ2618A1 (et)
EA (1) EA003184B1 (et)
EE (1) EE200000214A (et)
GB (1) GB9721139D0 (et)
GT (1) GT199800157A (et)
HN (1) HN1998000155A (et)
HR (1) HRP20000198A2 (et)
HU (1) HUP0003750A3 (et)
ID (1) ID23874A (et)
IL (1) IL135398A0 (et)
IS (1) IS5425A (et)
MA (1) MA26549A1 (et)
NO (1) NO20001776L (et)
NZ (1) NZ503698A (et)
PA (1) PA8461101A1 (et)
PE (1) PE120299A1 (et)
PL (1) PL340337A1 (et)
SK (1) SK4862000A3 (et)
SV (1) SV1998000122A (et)
TN (1) TNSN98179A1 (et)
TR (1) TR200000913T2 (et)
UY (1) UY25200A1 (et)
WO (1) WO1999017755A2 (et)
YU (1) YU20600A (et)
ZA (1) ZA989061B (et)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6136807A (en) * 1998-11-10 2000-10-24 3M Innovative Properties Company Composition for the transdermal delivery of lerisetron
EP1090638A1 (en) * 1999-10-08 2001-04-11 Sanofi-Synthelabo Use of (R)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea
TWI263496B (en) * 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
DE10015783C2 (de) * 2000-03-30 2003-12-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung
WO2001087305A2 (en) * 2000-05-18 2001-11-22 Glaxo Group Limited Method for treating functional dyspepsia using alosetron
US6566369B2 (en) 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
AR028970A1 (es) * 2000-07-26 2003-05-28 Solvay Pharm Gmbh USO DE CILANSETRON O DE SUS SALES POR ADICIoN DE A CIDOS Y/O SOLVATOS FARMACOLoGICAMENTE COMPATIBLES PARA LA OBTENCIoN DE PREPARADOS FARMACEUTICOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DEL SíNDROME DEL INTESTINO IRRITABLE
WO2002020841A2 (en) * 2000-09-06 2002-03-14 Glaxo Group Limited 5-hydroxytryptamine receptor gene polymorphisms and response to treatment
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
EP1395289B1 (en) * 2001-06-07 2010-12-15 Christine Dr. Sang Treatment of neuropathic pain with a n-methyl-d-aspartate (nmda) receptor antagonists
US7045549B2 (en) * 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
CA2473392A1 (en) 2002-01-18 2003-07-31 Aryx Therapeutics 5-ht3 receptor antagonists and methods of use
CA2491836C (en) * 2002-07-10 2011-01-25 Arachnova Therapeutics Ltd. 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder
DE10232750A1 (de) * 2002-07-18 2004-02-05 Basf Ag Verfahren zur Herstellung von macrocyclischen Ketonen durch Dieckmann-Kondensation in der Gasphase
JP4399862B2 (ja) * 2002-08-09 2010-01-20 味の素株式会社 腸疾患および内臓痛の治療薬
US20030187017A1 (en) * 2002-11-14 2003-10-02 Mangel Allen Wayne Method for treating functional dyspepsia
JP2006516977A (ja) * 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
NZ541008A (en) * 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating functional bowel disorders
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
ZA200409537B (en) * 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
JP2007514000A (ja) * 2003-12-16 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド テガセロッド塩基及びその塩の多形現象形
US7358270B2 (en) 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome
WO2005073220A1 (ja) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. 下痢型過敏性腸症候群治療剤
MXPA05009025A (es) * 2004-01-30 2006-04-27 Astellas Pharma Inc Agentes de tratamiento para el sindrome de intestino delgado irritado con diarrea predominante.
JP3763360B2 (ja) * 2004-01-30 2006-04-05 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
WO2005076824A2 (en) * 2004-02-03 2005-08-25 The Regents Of The University Of California Methods of treating irritable bowel syndrome
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1724267B1 (en) * 2004-02-26 2013-11-06 ASKA Pharmaceutical Co., Ltd. Pyrimidine derivative
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7317022B2 (en) * 2005-06-07 2008-01-08 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
JP4632204B2 (ja) * 2005-09-21 2011-02-16 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
US7985764B2 (en) * 2006-02-20 2011-07-26 Astellas Pharma Inc. Amide derivative or salt thereof
WO2009053750A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline and amorphous forms
WO2009053733A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
WO2009053732A1 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel salt
WO2009053754A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
US8343552B2 (en) 2007-12-28 2013-01-01 Liveleaf, Inc. Therapeutic composition produced using punica granatum and hydrogen peroxide
US8734867B2 (en) * 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
ES2639364T3 (es) 2009-04-29 2017-10-26 Ganeden Biotech, Inc. Formulación de membrana celular bacteriana
WO2011001954A1 (ja) * 2009-06-30 2011-01-06 アステラス製薬株式会社 緩解期の炎症性腸疾患患者における排便異常治療剤
JP5938886B2 (ja) * 2010-12-14 2016-06-22 アステラス製薬株式会社 活動期の炎症性腸疾患患者における排便異常治療剤
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
US20120329736A1 (en) * 2011-06-24 2012-12-27 Huang Alexander L Treatment for gastrointestinal disorders using a selective, site-activated binding system
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
DK2744497T3 (en) * 2011-10-18 2016-08-01 Helsinn Healthcare Sa THERAPEUTIC COMBINATION OF netupitant AND palonosetron
BR112015004902A2 (pt) * 2012-09-05 2017-07-04 Chase Pharmaceuticals Corp métodos e composição neutroprotetores anticolinérgicos
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254584B1 (en) * 1986-07-25 1992-10-07 Beecham Group Plc Azabicyclic compounds, process for their preparation, and their pharmaceutical use
GB8806990D0 (en) * 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
DE3851597T2 (de) * 1987-09-03 1995-01-26 Glaxo Group Ltd., London Lactamderivate.
DE3850742T2 (de) * 1987-11-04 1994-10-27 Beecham Group Plc Neue 4-Oxobenzotriazine und 4-Oxochinazoline.
JPH0249772A (ja) * 1988-04-07 1990-02-20 Glaxo Group Ltd イミダゾール誘導体
GB8814277D0 (en) 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds
US5017573A (en) * 1988-07-29 1991-05-21 Dainippon Pharmaceutical Co., Ltd. Indazole-3-carboxylic acid derivatives
GB8820650D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
GB8829079D0 (en) * 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
GB8904551D0 (en) * 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
EP0387431A1 (en) * 1989-03-14 1990-09-19 Beecham Group Plc Imidazole derivatives, process for their preparation and their pharmaceutical use
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
GB9027098D0 (en) * 1990-12-13 1991-02-06 Beecham Group Plc Pharmaceuticals
GB9027487D0 (en) 1990-12-19 1991-02-06 Beecham Group Plc Pharmaceuticals
EP0566609A1 (en) * 1991-01-09 1993-10-27 Smithkline Beecham Plc Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
GB9214184D0 (en) 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
UY25200A1 (es) 2001-01-31
GT199800157A (es) 2000-03-30
MA26549A1 (fr) 2004-12-20
TNSN98179A1 (fr) 2005-03-15
ZA989061B (en) 2001-07-05
EA200000299A1 (ru) 2000-12-25
US20010044450A1 (en) 2001-11-22
HRP20000198A2 (en) 2001-04-30
WO1999017755A3 (en) 1999-09-23
AP2000001785A0 (en) 2000-06-30
CO5011096A1 (es) 2001-02-28
HUP0003750A3 (en) 2003-02-28
IS5425A (is) 2000-03-31
WO1999017755A2 (en) 1999-04-15
AU9629398A (en) 1999-04-27
GB9721139D0 (en) 1997-12-03
EE200000214A (et) 2001-06-15
NZ503698A (en) 2002-10-25
CA2305751A1 (en) 1999-04-15
YU20600A (sh) 2003-10-31
IL135398A0 (en) 2001-05-20
PE120299A1 (es) 1999-12-15
US20030036549A1 (en) 2003-02-20
EA003184B1 (ru) 2003-02-27
US6284770B1 (en) 2001-09-04
DZ2618A1 (fr) 2003-03-01
HN1998000155A (es) 1999-05-24
CN1281357A (zh) 2001-01-24
AU750818B2 (en) 2002-07-25
US6429209B2 (en) 2002-08-06
KR20010015707A (ko) 2001-02-26
US6593336B2 (en) 2003-07-15
NO20001776L (no) 2000-06-06
BR9812886A (pt) 2000-08-08
PL340337A1 (en) 2001-01-29
EP1021174A2 (en) 2000-07-26
ID23874A (id) 2000-05-25
JP2001518495A (ja) 2001-10-16
SV1998000122A (es) 1999-07-05
AR017296A1 (es) 2001-09-05
TR200000913T2 (tr) 2001-01-22
NO20001776D0 (no) 2000-04-06
HUP0003750A2 (hu) 2001-10-28
PA8461101A1 (es) 2000-05-24

Similar Documents

Publication Publication Date Title
SK4862000A3 (en) The use of 5-ht3 receptor antagonists
DE60106281T2 (de) Verfahren zur Behandlung eines Östrogenrezeptor-positiven Karzinoms
TWI389689B (zh) 氟利本西林（ｆｌｉｂａｎｓｅｒｉｎ）於治療停經前性慾疾病之用途
US20040006120A1 (en) Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
DE602004005814T2 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
KR100469029B1 (ko) 세로토닌재흡수억제제의위장효과를극복하기위한5ht4수용체길항제의용도
ITMI941048A1 (it) Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
SK281603B6 (sk) Použitie 5ht3 antagonistu na prípravu farmaceutickej zmesi na liečenie fibromyalgie
EA030145B1 (ru) Комбинации агонистов бета-3-адренергических рецепторов и антагонистов мускариновых рецепторов для лечения гиперактивности мочевого пузыря
US20130045988A1 (en) Combination therapy
EP1276476A2 (de) Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen
EP4009977A2 (en) Compositions and methods for the treatment of estrogen-dependent disorders
US5155126A (en) Treatment of central nervous system disorders with pyrazole, pyrrole and triazole angiotensin-II receptor antagonists
CA2362918A1 (en) Methods and compositions for treating erectile dysfunction
CZ287441B6 (en) Pharmaceutical preparation for treating traumatic lesion of brain
US4312879A (en) Clonidine and lofexidine as antidiarrheal agents
RU2181047C2 (ru) Способ ингибирования состояний, ассоциированных с брадикинином
DE3904795C2 (de) Pharmazeutisches Präparat und dessen Verwendung
CZ20001259A3 (cs) Farmaceutický prostředek
RU2761219C2 (ru) Терапевтическое средство от расстройств, связанных с употреблением алкоголя
US4363809A (en) Organic compounds
CZ2001150A3 (cs) Lék pro léčbu psychóz nebo jiných neuropsychiatrických příznaků u pacientů s Alzheimerovou chorobou
MXPA00003375A (en) Medicaments
DE3705220A1 (de) Mittel zur behandlung von coronarerkrankungen oder organischem hirnsyndrom
JPH07503968A (ja) ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンの浮腫および痛みの治療のための使用